THEMIS2 and breast carcinoma: Notably, CCR6 encodes a chemokine receptor that has been involved in inflammatory and infectious diseases and that is associated with several cancers through immune cell control [53], while SMPDL3B is involved in innate immunity and may be used as a prognostic biomarker in human cancers, such as myeloid leukemia and ductal carcinoma [54,55], and THEMIS2 is expressed in a variety of cancer types and cell lines and was recently found to have tumor-suppressive role in breast cancer [56].